This Year's Highlights

• AllTranz, Inc. has recently completed an approx. $1.85 million total financing. AllTranz plans to impact the $40 billion pain management market with the development of prodrug strategies that work with transdermal delivery products.
• Both LDG Sleep Technologies, Inc., developing a serum-based diagnostic for obstructive sleep apnea, and ImmunoTheragnostics Incorporated, developing diagnostics for women?s health, have been awarded $200,000 R&D Vouchers by KSTC.
• RhinoCyte, Inc. closed a $930,000 Series A financing in June 2006. RhinoCyte is developing uses of autologous adult stem cells derived from the olfactory epithelium. The company?s lead indication is spinal cord injury.

Anticipated Highlights

• Pradama Inc. expects to close a $1.1 million Series A financing on August 31, 2007. Pradama is a specialty pharmaceutical company focused on the development and commercialization of products to treat bone diseases and disorders.
• ApoImmune Inc. plans to seek a $3-$5 million Series B financing within the next twelve months. ApoImmune is developing immunotherapies. The company?s lead indication is cervical cancer.

Corporate Mission

MetaCyte Business Lab works to help both the University of Louisville and Louisville Metro achieve their mutual goal of becoming a nationally recognized center of life science activity and commercialization. The MetaCyte team does this by creating life science companies.

MetaCyte is a team which collectively has over 120 years of experience in the health science industry and over 20 years experience in venture capital. Members of the team have started companies and secured capital to fund them?in excess of $75 million, at last count. Individuals have experience in basic science research. In addition, the team has experience in launching pharmaceutical products in the market?products with more than $6 billion in sales. Skills and expertise span the entire health science continuum.

It is this entrepreneurial team that becomes the management team for start-up life science companies in the MetaCyte portfolio. MetaCyte takes an equity position in its portfolio companies at creation. Our only compensation will be the value we help create?we?re ?holding on to the burlap,? too.

Think of MetaCyte as a ?manufacturing company? whose products are life science and healthcare technology start-ups. MetaCyte proactively identifies raw material (intellectual property) principally from the Louisville Medical Center and turns that raw material into products?life science and healthcare technology start-ups. MetaCyte?s customers are professional investors in life science and healthcare technology companies.

Again, our mission is to create companies that investors have confidence in and value highly.